. Incidence of systemic sclerosis is twice as frequent in black compared with white populations 4 , and the disease is between twofold and fourfold more common in women than in men; peak age of disease onset is 30-50 years 2, 3 . Systemic sclerosis is classified as either diffuse or limited cutaneous disease, based on the extent of skin involvement, with limited systemic sclerosis accounting for ~80% of diagnoses 5 . Patients with limited systemic sclerosis have skin thickening (scleroderma) only distal to the elbows and knees, but the face can be affected in those with diffuse or limited disease. This classification also defines the organ involvement, autoantibody profile and clinical progression of the disease 6, 7 . Diffuse disease is characterized by positivity for anti-Scl-70 (also known as anti-topoisomerase 1) antibodies, early and rapid organ involvement and a poor prognosis. Limited systemic sclerosis is characterized by positivity for anti-centromere antibodies, slow disease progression, visceral involvement later in the disease course and a better prognosis than diffuse disease. Involvement of the gastrointestinal tract can be found in either form, but is more common in patients with diffuse disease 7 . Gastrointestinal symptoms are seen in up to 90% of all patients with systemic sclerosis, and are the presenting feature of disease in 10% of individ uals 8 . Gastrointestinal involvement is the leading cause of morbidity and third most common cause of mortality in patients with systemic sclerosis, with cardiopulmonary and renal involvement being the first and second most common causes, respectively 8 .
Gastrointestinal involvement
Vascular endothelial hyper-reactivity, manifested as recurrent episodes of vasoconstriction and reperfusion, has been hypothesized to be the initial pathological event in the development of systemic sclero sis 9 . Sequential histological studies of enteric smooth muscles from patients with systemic sclerosis suggest that the initial trigger for this vascular instabil ity is autonomic axonal degeneration, specifically sympathetic overactivity 10, 11 (FIG. 1) . Alternatively, the initiating event has also been hypothesized to be autoimmune related, on the basis of immunohistochemical studies showing the presence of circulating IgG autoantibodies against myenteric neurons in many patients 12 .
Currently available data support a combination of the autoimmune and autonomic aetiology hypotheses, with the identification that circulating IgG autoantibodies are capable of disrupting intestinal myoelectrical function 12, 13 . Specifically, patients with systemic sclerosis express antibodies to the muscarinic acetylcholine receptor M3, which is critical for the control of intestinal peristalsis by the enteric nervous system 13, 14 . Patients with more severe gastro intestinal phenotypes have increased expression of these antibodies, supporting a causal link between antibody levels and gastrointestinal systemic sclerosis features 14 . Whatever the aetiology of the disease, vascular instabil ity is thought to progress to tissue ischaemia, and subsequently altered mucosal immunity and tissue repair (FIG. 1) . Tissue repair in patients with systemic sclero sis is characterized by excessive collagen and collagen matrix deposition, resulting in fibrotic replacement of tissue in the skin and internal organs, including in the gastrointestinal tract 15 . Fibrosis involves both the gut smooth muscle and the smooth muscle of the gastrointestinal vasculature 16 . This fibrotic infiltration results in dysmotility and delayed transit time, which can affect any gastrointestinal region from the oral cavity to the anus 9, 17, 18 (FIG. 2) .
Gut involvement can progress rapidly (within years) or slowly (within decades) for diffuse and limited systemic sclerosis, respectively 19, 20 . However, several studies have failed to show any correlation between gastro intestinal symptoms and severity of gastrointestinal physiological compromise in systemic sclerosis 9, 11 . There also seems to be no correlation between patient-reported severity of gut symptoms and degree of morbidity of systemic sclerosis 21 . Severe gastrointestinal involvement, especially small bowel involvement presenting with malabsorption and dysmotility, is associ ated with increased mortality in some series 5, 22 . This finding emphasizes the importance of early and continuous monitoring (via regular clinical assessment) of gastro intestinal tract involvement in patients with systemic sclerosis to avoid these severe syndromes of small bowel failure 23 . Optimal monitoring assessments and emerging potential therapies are detailed in this Review, which will be structured around presentation symptoms and syndromes, rather than anatomical location, so as to have the greatest utility to the clinician seeing these patients.
Dysphagia
Although oesophageal dysmotility is the most common gastrointestinal manifestation of systemic sclerosis 19, 24, 25 , it is vital to consider that dysphagia might be caused by a GERD-related stricture (discussed later), and hence an upper gastrointestinal endoscopy might be appropriate to exclude this possibility. In turn, however, the absence of oesophageal symptoms does not necessarily exclude oesophageal involvement as physiological change might precede symptom development 21, 26 . Whether the prevalence and severity of oesophageal dysmotility is related to the extent or severity of cutaneous systemic sclerosis involvement is unclear 27, 28 . Oesophageal manometry has superseded scintigraphy and barium radiography as a diagnostic modality as it is more reproducible, more easily interpretable and more readily available. Highresolution manometry might reveal more about the pathophysiology of dysphagia in systemic sclerosis, given its ability to demonstrate subtle topographic change not necessarily picked up by conventional manometry. The characteristic oesophageal motility abnormalities in patients with systemic sclerosis include the following: reduced (or absent) lower oesophageal sphincter pressure; ineffective oesophageal body peristalsis (especially in the distal oesophagus); and incoordination of peristaltic and lower oesophageal sphincter function 9, 16, [28] [29] [30] . Pharyngeal and proximal oesophageal motility is normal in systemic sclerosis, which might reflect the relative sparing of somatic innervation of the proximal oesophagus, compared with impaired visceral innervation of the distal oesophagus 31 . To date, no pharmacological intervention has been shown to influence the development of the oesophageal complications of systemic sclerosis and, consequently, treatment focuses on symptomatic management with prokinetic agents 23 . Prokinetic agents stimulate gut peristalsis through a direct receptor-binding mech anism on enterocytes; by contrast, laxatives tend to have a nonspecific mucosal contact action. Considerable data exist on the acute manometric effects of pro kinetics such as metoclopramide, erythromycin, bethanechol, buspirone and domperidone, and these studies have been reviewed elsewhere 27 , but no formal studies have been published on the use of these agents in clinical practice in patients with systemic sclerosis. Prucalopride might have a role as a prokinetic, given its mechanism of increasing choliner gic tone in the gut and hence enhancing peristalsis in the upper and lower gastrointestinal tract 32, 33 . In any event, prokinetic agents probably have no effect in advanced systemic sclerosis, as smooth muscle atrophy would preclude their being beneficial. In terms of non-pharmacological therapies, a study of patients with early systemic sclerosis suggested a role for lowfrequency electrical acupuncture stimulation to improve dysphagia 34 . This technique involves the insertion of stainless steel acupunc ture needles at desig nated points and attached to an electrical stimulator at variable frequencies, the intensity being adjusted to produce local muscle contractions without pain and discomfort. Treatment duration varied from 3 months to 9 years. The uncontrolled study included 34 patients with
Key points
• Gut involvement in systemic sclerosis occurs more commonly in the diffuse than the limited cutaneous variant • Oesophageal involvement is the most common gastrointestinal manifestation of systemic sclerosis, with severe reflux disease and dysphagia as the main presentations • When treating small intestinal bacterial overgrowth in patients with systemic sclerosis, effectiveness of treatment and decisions about cyclical courses of antibiotic are best assessed by symptoms rather than breath testing • Malnutrition in patients with systemic sclerosis is associated with more aggressive disease progression, and the risk of developing malnutrition is related to both gut and extraintestinal factors systemic sclerosis and showed modest clinical benefits in tandem with modest changes in inflammatory markers from cutaneous biopsy tissue taken before and after treatment. Transcutaneous electrical nerve stimulation (TENS) has not shown efficacy in patients with more advanced disease 35 . High-frequency TENS applied during oesophageal manometry produced no change in any motility parameters. No data exist on low-frequency TENS or use of TENS in patients with early systemic sclerosis.
GERD
The manometric features described earlier demonstrate a strong predisposition in patients with systemic sclerosis to pathological GERD; more than three-quarters of patients with systemic sclerosis have erosive reflux changes in the oesophagus 36 , and degree of erosion corre lates with change and severity of dysmotility 37 . As such, monitoring of patients with systemic sclerosis by simultaneous recording of oesophageal pH and manometry has been recommended, regardless of the presence or absence of reflux symptoms 38 . 50% of patients with systemic sclerosis have delayed gastric emptying 16, 39, 40 , which also predisposes to GERD. The severity and chronicity of GERD in patients with systemic sclerosis results in high rates of stricturing, and the development of Barrett oesophagus in 40% 41 .
Conservative therapy of GERD symptoms (lifestyle modification, postural assistance and dietary modification) has not been formally studied in patients with systemic sclerosis, but given the severity of physiological disturbance in these individuals such treatments are rarely effective in isolation 41, 42 . Nevertheless, eating small meals, avoiding meals shortly before recumbence, reducing fat intake and ceasing smoking are all reasonable approaches 27, 42 . PPIs are the core of GERD maintenance therapy, and might need to be used in double or even quadruple doses in patients with systemic sclerosis 43, 44 . Given the increasingly well-recognized adverse effects of chronic PPI use 45 and the need for chronic therapy in patients with systemic sclerosis, counselling patients at initiation of treatment is important. Adverse effects relevant to patients with systemic sclerosis are the association of PPIs with osteopenia, intestinal infection (including small intestinal bacterial overgrowth (SIBO)) and interaction with antiplatelet therapies 46 . Based on a comparator study with the 5-hydroxytryptamine receptor 2 (also known as serotonin receptor 2) agonist cimetidine, use of antacids is not supported in systemic sclerosis 47 , but provided that aluminium-containing agents (which can cause constipation) are avoided, they might be a low-risk alternative. The efficacy of adding 5-hydroxytryptamine receptor 2 agonists to PPIs to improve GERD symptoms has not been studied in patients with systemic sclerosis, yet benefit is minimal in patients with GERD who do not have systemic sclerosis 48 . More aggressive modalities such as endoscopic or laparoscopic antireflux procedures are also unreported in systemic sclerosis and are best avoided as they are likely to be complicated by dysphagia, given the known severe dysmotility in these patients 9, 16 . A key focus of GERD therapy is to avoid progression to more complex manifestations such as oesophageal strictures or Barrett oesophagus 23 . Endoscopic dilatation is indicated in the ~30% of patients with systemic sclerosis who develop strictures, which manifests as progressive dysphagia 49 , in addition to optimizing PPI therapy to minimize stricture recurrence. Prospective studies of Barrett oesophagus in patients with systemic sclerosis showed an annual 3% rate of progression to high-grade dysplasia and 0.7% incidence of oesophageal adenocarcinoma 50, 51 . Discussion of the frequency of screening for Barrett oesophagus is beyond the scope of this Review, but the high incidence of high-grade dysplasia in patients with systemic sclerosis mandates frequent endoscopic monitoring. No guidance exists on the frequency of such monitoring, but it should be influenced by multidisciplinary assessment of severity of symptoms, degree of histological disease severity and rate of histological change.
An emerging important complication of GERD seems to be the role of microaspiration of gastric content as a driver of interstitial lung disease. Initial data in a rat model showed that gastric content introduced into the lung caused a parenchymal fibrotic reaction 52 . This finding has been supplemented by data in patients with systemic sclerosis, correlating an increased degree of lung fibrosis with more frequent reflux episodes and greater proximal extent of refluxate 53 . The relationship between reflux and development of pulmonary involvement is equivocal: 50% of patients with systemic sclerosis with severe reflux associated with lung disease risk were asymptomatic from the oesophageal perspective, and progression of lung disease was not associated with progressive hypomotility 54, 55 . As yet no trial data has shown improvement in the lung function of patients with systemic sclerosis after aggressive GERD management. However, prospective cohort data on progression of oesophageal motility and pulmonary pathophysiology supports the use of PPIs with add-on prokinetic agents, even in asymptomatic patients 54 . This view has been endorsed by the identification of a novel histological form of lung disease, known as centrilobular fibrosis, which is seen especially in those patients with systemic sclerosis who also have severe GERD 55 .
Vomiting and abdominal pain
Delayed gastric emptying is seen in ~50% of patients with systemic sclerosis 56, 57 . This functional delay seems to relate to both structural changes (reduced gastric size) 40 and slowing of gastric electrical activity associated with the autonomic nerve 38, 58 . The typical gastro paresis symptoms of abdominal bloating, pain, early satiety and vomiting are more commonly reported in diffuse rather than limited cutaneous systemic sclero sis 59 . None of these features are unique to systemic sclerosis, as they are also observed in functional dyspepsia as well as other causes of gastroparesis such as diabetes mellitus 60 . As such, these symptoms cannot be recommended as clinically useful for diagnosis of systemic sclerosis or monitoring of the disease. This aspect is especially disappointing because the correlation between symptom burden and objective abnormalities is poor 59 , leaving no widely accepted gold standard to measure outcome.
As with GERD management, there is no evidence specific for patients with systemic sclerosis in support of lifestyle and dietary therapies to manage delayed gastric emptying. Low-residue diets (which reduce stool frequency and liquidity by reducing intake of fibre and gut stimulants, such as dairy products) and vitamin supplementation have been recommended on an empirical basis 9 . Equally disappointing is the lack of efficacy of prokinetic and antiemetic drugs in patients with systemic sclerosis. With regards to pro kinetics, erythromycin (as opposed to domperidone) has been studied in this patient group 61 , but accelerates gastric emptying at a dose (200 mg) that also inhibits small bowel motility 62 . Symptom response data beyond 33 weeks for erythromycin is lacking, and the drug is most effective in early disease, before smooth muscle atrophy and fibrosis set in 61 . A consensus guideline on the management of gastro paresis in general suggested that the liquid formulation of metoclopramide can be considered if no neurological or electrocardiographic adverse effects develop, although no specific evidence exists for gastroparesis in Nature Reviews | Gastroenterology & Hepatology the context of systemic sclero sis 62 . Octreotide does not seem to have an effect on gastric emptying or gastroparetic symptoms 63 . A placebo-controlled crossover study of infusion with the gastric-derived prokinetic hormone ghrelin 64 in 10 patients with systemic sclerosis showed an acceleration of gastric emptying (53 minutes saline versus 43 minutes ghrelin) 65 , raising the potential for ghrelin analogues as therapy. Jejunal feeding can be considered in situations in which there is symptomatic delay in gastric emptying in the presence of normal small bowel transit 66 : this treatment and parenteral nutrition are discussed in detail later. A single-centre study of TENS has shown short-term (over 2 weeks) efficacy in improving gastroparesis symptoms associated with systemic sclero sis 67 . Surgical procedures such as venting gastrectomy or antrectomy are associated with major long-term complications 68 and should only be considered in the most extreme of situations such as intractable vomiting, anorexia and profound progressive weight loss 9 .
Small intestinal bacterial overgrowth
The clinical symptoms of SIBO are abdominal bloating, flatulence, early satiety, postprandial nausea and, occasionally, diarrhoea 21, 27, 42 . Disturbances of small intestinal motility and immunity can be compounded by hypo chlorhydria secondary to PPI usage and hence pre dispose to migration and colonization of the small intestine by colonic microbiota 69, 70 . If not corrected, SIBO can result in malnutrition, so treatment is essential not just from the symptom-relief perspective. Hydrogen breath testing (after either a glucose or lactulose meal) is widely used as the clinical standard for diagnosis of SIBO, but analyses in the past few years have shown that the specificity and sensitivity of such testing is no better than 68% and 44%, respectively 71, 72 . However, the intrusiveness and comparative expense of the research standard, upper gastrointestinal endoscopy with culture of duodenal aspirate 70 , makes breath testing the most widely used, and in the author's opinion the most valid, modality for diagnosis. The alternative to testing for SIBO is to treat empirically with broad-spectrum antibiotics (against both aerobic and anaerobic strains) to modify the microbiota sufficiently to result in symptomatic improvement, rather than attempting to eradicate the specific strain 73 . Antibiotic therapy is as effective at improving SIBO symptoms in patients with systemic sclerosis 74 as it is in patients with IBS 72 . A meta-analysis 75 of antibiotic therapy for SIBO (caused by a variety of aetiologies beyond just systemic sclerosis) published in 2013 identified SIBO symptom improvement in approximately two-thirds of patients, with no statistically significant advantage of any one agent over another. Antibiotics used in the treatment of SIBO in the analysed trials include amoxicillin, ciprofloxacin (and other quinolones), doxycycline (and other tetracyclines), metronidazole, rifaximin (and other minimally absorbable antibiotics) and trimethoprimsulfamethoxazole. The outcome of the meta-analysis was the recommendation to use any of these antibiotics for 10-14 days and to monitor outcome by symptoms rather than breath testing, given the poor sensitivity of the latter technique 75 . In the clinical context of systemic sclerosis, in which SIBO can recur owing to the underlying pathophysiology in the gut, some experts argue in favour of cyclical courses of antibiotic for patients with recurrent proven SIBO (by culture of an endoscopically obtained duodenal aspirate)-for example, 10-14 days treatment every month, rotating between the antibiotics listed previously to protect against the development of antibiotic resistance 21, 75, 76 . An alternative treatment strategy in this situation is to give a probiotic rather than antibiotic when the initial course of antibiotic is withdrawn, although no clear evidence exists to recommend any specific product 77 . Probiotic treatment is supported by a small body of clinical trial data in idiopathic SIBO 78 as well as SIBO associated with systemic sclerosis 79 , but definitive controlled trials are needed before such an approach can be unequivocally advocated.
Malnutrition
Malnutrition in patients with systemic sclerosis is usually multifactorial in origin. Oral food intake is often reduced as a result of the persistent and debilitating symptoms of nausea, vomiting and early satiety caused by gut dysmotility 80 , and SIBO can cause maldigestion and malabsorption of specific nutrients. The basic assessments suggested by an expert USA panel comprised full blood count and serum levels of haemoglobin, vitamin A, folic acid, ferritin and vitamin B 12 (REF. 77 ). In addition, extraintestinal contributors to malnutrition are often present in patients with systemic sclerosis: perioral sclerosis means that patients tend to eat a low-residue diet with decreased mineral and vitamin intake due to mechanical and pain factors when trying to eat fruits and vegetables; low intake of nutrients is often exacerbated by oesophageal dysmotility 80 . In addition, finger contractures can make preparing and eating meals arduous. Finally, low mood and adverse effects of concomitant therapy (such as calcium channel antagonists, prostaglandin derivatives, immune suppressants and opioids) can reduce appetite 21, 80 . Malnutrition develops insidiously and so the correct choice of screening modality is unclear. A study using the malnutrition universal screening tool (MUST) 81 identified that 28% of a cohort of 586 patients with systemic sclerosis in Canada were at medium (MUST score of 1) or high risk (MUST score >2) of malnutrition 82 . Increased risk was associated with the degree of gastro intestinal symptomatology assessed by trialspecific questionnaire, shorter disease duration and overall systemic sclerosis disease severity (gauged by physician rating) 82 . Thus, both gut and extraintestinal factors predict the risk of developing malnutrition. Given that malnutrition is associated with more aggressive disease progression 76, 80 , screening for malnutrition is recommended in all patients with systemic sclerosis. Whether this association is causal remains to be determined by suitably designed prospective cohort studies. This screening should be considered with the MUST tool 23, 82 , a gastrointestinal symptom assessment (using a questionnaire such as the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract (UCLA SCTC GIT) 2.0 instrument, discussed in detail later 83 ) and serology comprising full blood count, haematinics tests, and levels of serum carotene and prealbumin 42, 77, 80 (FIG. 3) . Such screening is supported by the observation that nutritional treatment improves nutritional status 84 and, hopefully, will in turn improve survival; however, prospective long-term studies are required to confirm this hypothesis.
The key to managing patients with malnourishment related to systemic sclerosis is to have a framework for practice, underpinned by close multidisciplin ary cooperation between gastrointestinal and rheumatological teams 77, 80 (FIG. 3) . In the author's opinion, if pres ent, SIBO should be treated first. In addition, gastrointestinal radiology to exclude chronic intestinal pseudoobstruction (CIPO, discussed in more detail later) is recommended 23 ; if gut dilatation suggestive of CIPO is observed then a trial of prokinetic therapy is appropriate.
If the patient remains malnourished or symptomatic despite these medical therapies then they might need to be considered for enteral nutrition 80 , either by temporary transnasal or more permanent endoscopic tube insertion (FIG. 3) . On the basis that gastroparesis can be severe in patients with systemic sclerosis, the enteral feed is preferably jejunal rather than gastric 23, 80 . If enteral feeding is not practicable or successful and malnutrition continues, consideration of parenteral feeding is appropriate 85 . Despite the well-recognized complications of this approach, which include deterioration of liver function, catheter sepsis and venous thrombosis, the benefits in terms of weight gain and quality of life of home parenteral feeding have been established in patients with systemic sclerosis 85 . Additionally, patients with systemic sclerosis are not at higher risk of these complications than patients with intestinal failure secondary to other causes 23, 85 .
Chronic intestinal pseudo-obstruction CIPO is characterized by clinical and radiological evidence of chronic episodic intestinal obstruction in the absence of a mechanical lesion 86 ; it occurs as a result of a visceral myopathy or neuropathy and can be primary or, more commonly, secondary to diseases such as systemic sclerosis 87 . As no mechanical lesion exists, a critical goal of treatment is to avoid surgery, which by definition cannot be curative 86 . Although a wealth of data exists about the natural history and poor prognosis of CIPO in general [86] [87] [88] , only one case-control series on patients with systemic sclerosis hospitalized with CIPO has been published 89 . Of 64 cases, a high proportion (9%) underwent surgical resection and an even larger proportion (16%) died. One-quarter of the 64 patients were given home parenteral nutrition. Mortality in this case-control series was associated with malnutrition at admission (reinforcing the importance of screening and treating this gastrointestinal complication of systemic sclerosis) and was higher in men than in women 89 . First-line therapy for acute CIPO is to rehydrate the patient, establish analgesia (preferably avoiding opioids that tend to exacerbate intestinal dysmotility) and decompress the bowel by nasogastric intubation 90 . Addressing nutritional needs early on is also important while waiting for CIPO symptoms to abate. Gut pro kinetic agents can help in this regard, whether or not they are being used in the chronic setting 91, 92 . As discussed earlier, metoclopramide and domperidone are often of little value 93 . Erythromycin at doses of 1.5-2 g per day can be of benefit in some patients with CIPO, including when CIPO is secondary to systemic sclero sis 91 . Intravenous neostigmine might help abort an episode of pseudo-obstruction, but cardiac and cholino mimetic adverse effects might preclude use in patients who are frail 94 . Subcutaneous octreotide, a somato statin analogue, has proved beneficial in several series of patients with systemic sclerosis with CIPO in terms of improving gut motility and alleviating symptoms [95] [96] [97] . Dosing commences at 50 μg twice a day, and can be increased to a maximum of 200 μg per day according to treatment response 95, 96 . A combination of oral erythro mycin and subcutaneous octreotide has been suggested 62 , but as the latter seems to delay gastric empty ing caution might be needed in patients with systemic sclero sis and a combin ation of CIPO and gastroparesis 62 . A newer, long-acting octreotide preparation could be a better tolerated alternative to the combination of erythromycin and daily subcutaneous octreotide for prevention of relapse 97 . Finally, prucalopride has been shown to reduce the frequency of relapse of patients with CIPO, including those with CIPO related to systemic sclerosis, in a 1-year placebo-controlled study 92 .
Anaemia
Anaemia in systemic sclerosis is often the anaemia of chronic illness 98 , and can be exacerbated by the presence of major systemic sclerosis complications such as renal impairment and pulmonary hypertension 99 . Anaemia can also occur as part of the malnutrition associ ated with SIBO and systemic sclerosis 80 . Gastric antral 
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Repeat screen annually vascular ectasia (GAVE) is a rare complication of systemic sclerosis (affecting 1-5% of patients with systemic sclerosis 100, 101 ) that can cause anaemia with or without overt gastrointestinal bleeding. Although GAVE has endoscopically characteristic appearances ('watermelon stomach' , so-called due to the appearance of stripes of ectatic vasculature among the oedematous gastric mucosa), the condition is defined histologically by mucosal capillary dilatation with fibrin thrombi, foveolar epithelial changes and fibromuscular hyper plasia 102 . GAVE is most prevalent in early diffuse cutaneous systemic sclerosis, which is characterized by rapid skin progression and a distinct antibody profile (anti-RNA polymerase III positivity) 102 . Management of GAVE in systemic sclerosis is conservative in the first instance, with iron supplementation and monitoring of haemoglobin levels (to minimize the duration of therapy, which can exacerbate constipation) 101 . Endoscopic therapy with a neodymium-doped yttrium aluminium garnet (Nd:YAG) laser or argon plasma coagulation is indicated if oral iron supplementation fails 103 . Efficacy is similar with both endoscopic treatments (about 90%) but multiple treatment sessions are often required with either modality [104] [105] [106] . However, argon plasma coagulation is generally preferred due to its lower cost and reduced risk of complications, specifically haemorrhage and the need for surgery 106 . In refractory cases in which expert endoscopy is available, evidence from individual series supports the use of endoscopic band ligation 107 , sclerotherapy 108 and cryotherapy 109 for the management of GAVE associated with systemic sclerosis. In those cases refractory to these endoscopic techniques, intravenous cyclophosphamide (albeit only in a case-series of three patients) 110 , as well as surgical antrectomy 111 have been used. Although effective, these therapies are associated with morbidity and a mortality of ~7%. In a randomized trial, high-dose chemotherapy followed by autologous haematopoietic stem cell transplantation (HSCT) has been shown to be superior to cyclophosphamide in improving skin and lung function as well as quality of life in patients with systemic sclerosis 112 , and a report published in 2015 showing a benefit for HSCT in patients with systemic sclerosis and GAVE raises the possibility of a more definitive (that is, curative) therapy for this gastrointestinal complication 113 .
Constipation
Altered colonic physiology is seen in 20-50% of patients with systemic sclerosis, and unlike upper gut involvement this condition is often asymptomatic 19, 27, 80 . Progressive colonic smooth muscle atrophy results in diminished or absent peristalsis 114 , markedly delayed colonic transit 115 and, rarely, colonic pseudoobstruction 96 . Occasionally systemic sclerosis can result in loss of colonic compliance and even stricturing 116, 117 . In view of these impairments of colonic physiology, and the possibil ity of common coincidental colonic disease (such as diverticulosis and neoplasia), structurally assessing the colon (using endoscopy or radiology) in a new presentation of constipation is important in patients with systemic sclerosis.
Because slow transit is a frequent accompaniment to systemic-sclerosis-associated constipation, a high dietary fibre intake is likely to be poorly effective and is associated with frequent bloating and flatulence 118, 119 . Optimizing liquid intake can be difficult, especially if the patient has renal involvement. Similarly, stimulant laxatives (such as senna or bisacodyl) are preferred over macrogol osmotic laxatives in this situation, as osmotic laxatives cause electrolyte loss 119 . Lactulose can be effective, but only usually for 1-3 months because bacterial catabolism of the drug develops; the drug is also associated with poor tolerability and the need for dose escalation 42, 118 . In uncontrolled single-centre series, a variety of prokinetic drugs have been shown to improve colonic motility (and to a lesser extent symptoms) in systemic sclerosis: metoclopramide 20-30mg per day 114 , domperidone (maximum daily dose is currently 30 mg per day in divided doses) 9 and prucalopride once a day (2 mg in all patients except over 65 year olds, in whom the dose is reduced to 1 mg) 33 have been shown to improve colonic motility, whereas erythromycin 120 and octreotide 9 seemingly have efficacy only on small intestinal motility. If successful, prolonged use of prokinetic agents is a reason able option given that the drugs seem well tolerated in the long-term with no evidence of tachyphylaxis 118, 119 . Surgical resection (with or without stoma formation) is a poor option for patients with systemic sclerosis given the potential for skin complications (poor wound healing, stoma prolapse or retraction) and prolonged ileus, but might be required in extreme cases, for example in patients with a perforation or those who are refractory to drugs 121, 122 . In those patients with systemic sclerosis and constipation refractory to drugs, less radical options such as colonic pacing (in which an electrical impulse generator is implanted to stimulate the right colon) 123 or sacral nerve stimulation 124 are appealing, but have not been studied specifically in patients with systemic sclerosis.
Air in the bowel wall (pneumatosis cystoides intestinalis) is a rare manifestation of systemic sclerosis in the colon 125 . This condition is usually inconsequential with no manifestation of symptoms, and is generally picked up by chance during abdominal radiology 126 . On very rare occasions, a pneumoperitoneum might occur if there is dissection or rupture of these subserosal cysts 127 .
Diarrhoea
Diarrhoea in a patient with systemic sclerosis might indicate alterations in upper gut function, not just colonic involvement. SIBO is an important consideration and evidence suggests that this condition can be identified in a patient with diarrhoea by the presence of raised faecal calprotectin levels 128 . Additional aspects of small bowel involvement can also contribute to a steatorrhoea-like presentation in systemic sclerosis 38, 76, 80, 129 , including: intestinal ischaemia secondary to mesenteric vasculopathy; impaired lymphatic drainage secondary to fibrosis; loss of small intestinal surface area and function secondary to fibrotic infiltration; bile acid malabsorption independent of SIBO; fructose intolerance; and amyloidosis as a consequence of chronic inflammation.
For patients with systemic sclerosis and diarrhoea, the primary goal is to treat the underlying causes of intestinal dysfunction as listed previously, with consideration for the use of antibiotics for SIBO and bile acid sequestrants for bile acid malabsorption 129 . If all of these causes of intestinal dysfunction have been excluded or treated and diarrhoea continues, using judiciously titrated low doses of loperamide is reasonable, but caution should be exercised to avoid precipitation of severe constipation and possibly even a bout of CIPO symptoms 23, 119 . A diet low in FODMAPs (Fermentable Oligosaccharides, Disaccharides, Monosaccharides And Polyols), which reduces the osmotic and fermentable substrate in the gut 130 , is useful in improving diarrhoea in idiopathic and organic disease 131 , and could have a role in treating diarrhoea in patients with systemic sclerosis, although this indication has never been studied.
Faecal incontinence
As many as 20% of patients with systemic sclerosis report faecal incontinence 132 , which leads to major effects on quality of life 133, 134 . The underlying pathology is atrophy and fibrosis of the smooth muscle of the internal anal sphincter 135 with excess distensibility of the anal canal 136 . The most common presentation with sphincter involvement is passive faecal incontinence or soiling 137 . The alternative presentation of anorectal involvement in systemic sclerosis is rectal prolapse 23, 80, 138 , which can in turn exacerbate faecal soiling as the sphincter is held open by the prolapse. Rectal prolapse in patients with systemic sclerosis results from accumulation of collagen in the rectum, which causes reduced rectal compliance and subsequent straining 139 . Anorectal involvement is characterized by reduced resting anal tone, reduced rectal balloon distensibility and an attenuated rectoanal inhibitory reflex 137, 138, 140 . When stools are loose (Bristol type 6 or 7) augmenting fibre intake can improve symptoms 137 , yet otherwise this dietary modification is of little benefit and can even cause abdominal bloating. Antidiarrhoeals, specifically loperamide, might improve diarrhoea, but need to be used carefully to avoid exacerbating constipation and straining, which in turn is associated with increased risk of prolapse 23, 141 . Suppositories can be used to optimize rectal evacuation without straining in this situ ation 23, 118 . Pelvic floor biofeedback has never been studied in patients with systemic sclerosis but does warrant consideration in this population, given the nature of anorectal involvement and the known potential for biofeedback therapies in treating Raynaud phenomenon in systemic sclerosis 142 . Sacral nerve stimulation has been studied extensively in anorectal dysfunction not related to systemic sclerosis 143, 144 and in patients with systemic sclerosis and faecal incontinence in a small, short-term (five patients with 24 month median follow-up) single-centre study 143 . However, a multisite report in a 10 patient cohort has suggested that although no safety concerns are associated with the technique, the overwhelming majority of patients with systemic sclerosis derive no sustained benefit to anorectal function from continued sacral neuromodulation 144 . A randomized placebo-controlled study published in 2014 has suggested that posterior tibial nerve stimulation could be an alternative effective method of neuromodulation and relief of faecal incontinence symptoms in systemic sclerosis 145 . Longterm follow-up of patients treated successfully in this study is needed to determine whether symptom relief is maintained.
Given potential tissue healing problems, surgery is best avoided in patients with systemic sclerosis and anorectal dysfunction. However, in the case of a severe rectal prolapse, surgical resection of the rectum and sigmoid colon is preferred to transanal mucosal procedures, which have a high failure rate related to breakdown of the suture line 139 .
Symptom questionnaires
Gastrointestinal involvement in patients with systemic sclerosis is common and protean in manifestation. The emphasis of effective management is on early recognition, accurate categorization of regional involvement and prompt treatment to prevent the development of severe acute or chronic complications. In particular, avoiding malnutrition is important given its association with a worse prognosis. To that end, the central role of a validated and reproducible questionnaire for patients with systemic sclerosis has been recognized. Khanna and colleagues have pioneered the development of the UCLA SCTC GIT 2.0 instrument to address this requirement 83 . This questionnaire is an update of an earlier version, and comprises seven subscales: reflux, distention and/or bloating, diarrhoea, faecal soilage, constipation, emotional well-being and social functioning, and a total gastro intestinal score. The UCLA SCTC GIT 2.0 been validated by other groups internationally in patients with limited and diffuse systemic sclerosis, and against measures of intestinal motility (oesophageal manometry and anorectal physiology) 21, 146 . In addition, the instrument also offers a potential standard against which research studies can quantify gastrointestinal symptom burden in individuals with systemic sclerosis. The instrument has been used in this way to quantify disease in patients with upper and lower gut symptoms 135, 146 . Allied to a nutrition tool such as MUST 81 , the UCLA SCTC GIT 2.0 is important in the symptom assessment of patients with systemic sclerosis, including patients with and without gastro intestinal symptoms. In a complex multi system disorder such as systemic sclerosis, a disease-specific questionnaire is probably of greater value than more generic question naires 147 , even rigorously developed patient-reported instruments such as the PatientReported Outcomes Measurement Information System (PROMIS) gastrointestinal symptom scale 148 . PROMIS has been shown to have construct validity in patients with systemic sclerosis, and is increasingly used in idiopathic gastrointestinal disorders including IBD and IBS 149 .
Summary of disease management
In patients with systemic sclerosis the gastro intestinal tract is the most commonly affected visceral system (FIG. 2) . Although oesophageal complications have received most recognition and study, any region of the gut can be involved. What is clear is that quality of life is reduced in patients with systemic sclerosis who develop gastrointestinal complications 7, 132 . TABLE 1 summarizes the diagnostic considerations according to symptom presentation when managing patients with systemic sclerosis. Owing to the high prevalence of severe reflux symptoms in patients with systemic sclerosis, pragmatic, evidence-based patient management begins with the use of PPIs to control reflux symptoms and potentially reverse oesophageal and pulmonary complications 54, 55 . The second most commonly involved gastrointestinal site in systemic sclerosis is the anorectum, and patients should be actively screened for symptoms of constipation, diarrhoea and faecal incontinence. Laxative therapy tailored to individual needs and combined with toileting and lifestyle advice can successfully treat many patients with constipation and minimize the risk of rectal prolapse. Diarrhoea has a variety of treatable causes that can be identified with fairly simple investigations 128, 135 . Faecal incontinence is a disabling symptom of anorectal involvement and might be amen able to neuromodulation therapy. As malnutrition is associated with increased disease severity and a poorer prognosis, active screening should be used to identify patients with this symptom and to target them for early intervention; screening can be accomplished by simple anthropometric measurements (such as BMI, circumferences of mid upper-arm and waist, triceps skin-fold thickness) but also by serial observation of the patient and the simple MUST tool. The key to success ful manage ment of this wide array of physically and socially disabling symptoms is early identification and symptom control, because at the current time no therapy can reverse the pathophysiology of systemic sclerosis involvement in the digestive tract. Given the wide range of manifestations of systemic sclerosis, multidisciplinary teams (MDT) have a preeminent role in the management of these patients: key members of the team should include a gastroenterologist, rheumatologist, dietitian and radiologist.
Future research directions
Given the prevalence of gastrointestinal symptoms in systemic sclerosis, a number of avenues for future research exist. Current questionnaires should expand beyond assessment of the frequency of symptoms to also include symptom severity and the effects on patient quality of life. Expansion of these tools requires validation of the new questionnaires in patients with limited and diffuse systemic sclerosis. The potential utility of gastrointestinal diagnostics (faecal calprotectin levels, selenium homocholic acid taurine (SeHCAT) testing and hydrogen breath testing) to identify occult inflammation, bile acid malabsorption and sugar intolerances needs exploration in symptomatic and asymptomatic patients with systemic sclerosis. In addition, clinical trials of novel gastrointestinal agents such as prokinetic agents (for example, prucalopride) or secretagogues (for example, linaclotide and lubiprostone) are required to ascertain whether these gut-mucosa-targeted agents, which act on specific mucosal receptors, have particular efficacy in those patient groups. If the results of such trials are positive, these therapeutic agents might prevent the progression of gastrointestinal dysfunction to intestinal failure
Conclusions
In patients with systemic sclerosis, gastrointestinal involvement is the most common cause of morbidity, and the third most common cause of mortality, and especially affects those patients with diffuse rather than limited disease. Oesophageal involvement, in the form of severe reflux and dysphagia, is also very common and requires treatment to alleviate symptoms and potentially to reduce pulmonary comorbidity. Malnutrition needs to be surveyed for and managed actively. Constipation and faecal incontinence might coexist; novel drug and neurostimulation treatments could offer therapeutic potential. When present, diarrhoea can have a variety of causes that should be examined for in order to tailor treatment.
